S1416- Phase II Randomized Placebo-Controlled Trial Of Cisplatin With Or Without Abt-888 (Veliparib) In Metastatic Triple-Negative Breast Cancer And/Or Brca Mutation-Associated Breast Cancer
Posted Date: May 15, 2019
- Investigator: Mahmoud Charif
- Specialties: Breast Cancer, Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to compare the efficacy of cisplatin with or without ABT-888 (veliparib) on progression-free survival in breast cancer patients and to compare the efficacy of cisplatin with or without ABT-888 (veliparib) on progression-free survival.
Criteria:
To Be Eligible: Patients Must Have Metastatic Triple Negative Breast Cancer, Age 18 Or Older, Must Have Completed Radiation, Hormonal, Or Chemotherapy Within 2 Weeks Of Registation, No Uncontrolled Medical Illness
Keywords:
Breast Cancer, Cancer, Phase Ii, S1416, Triple-Negative Brea
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com